BioMedNewsBreaks

TuesdayOct 26, 2021 12:12 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Upcoming Pain Therapeutics Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced that it will present at the 15th Annual Pain Therapeutics Summit. The event is slated to take place on Nov. 1-3, 2021, with Tryp’s presentation scheduled to begin at 11:15 a.m. Central Time / 12:15 p.m. Eastern Time on Nov. 1. Chairman and CEO Greg McKee will provide an overview of the company followed by a live question-and-answer session with emphasis on the chronic pain indications that Tryp is pursuing including fibromyalgia, phantom limb pain, and complex regional…

Continue Reading

FridayOct 22, 2021 12:34 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Identifies Market Gap, Launches ‘Desire Project’

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently launched its “Desire Project” to address and treat female hypoactive sexual desire disorder (“HSDD”) with MDMA-assisted psychotherapy. A first-of-its-kind study, the Desire Project, is targeting HSDD, a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. The study comprises some of the world’s leading researchers in female sexual desire and psychedelics. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from the…

Continue Reading

FridayOct 22, 2021 12:25 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Facilitating Improved Diabetes and Prediabetes Management

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing diagnostic devices and supporting personalized lifestyle coaching programs. Its flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor designed to help people with diabetes and prediabetes manage their glucose levels. “Over 420 million people globally are currently living with diabetes, with prediabetic cases totaling almost three times that number,” reads a recent article. “Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.” To view…

Continue Reading

FridayOct 22, 2021 12:16 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is combined with protein-based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information,” explains a recent article. “Unlike most liquid-based cancer screening and detection methods, the CDA platform from AnPac Bio focuses on assessing the existing protein-based…

Continue Reading

FridayOct 22, 2021 12:02 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Well Qualified to Provide Global Insight into Medical Cannabis

RYAH Group (CSE: RYAH), a connected device and big data and technology company, in a recent blog post provided insight into the cannabis medical space in Brazil, the largest South American country both in size and population, boasting a GDP per capita of $15,388. A recent article that contains excerpts from the post notes that medical cannabis in Brazil may face some steep political hurdles but that the waves of reform are slowly making it possible for more patients to access more medicine. “While the country has faced challenges, RYAH notes that Brazil seems poised at the top of a…

Continue Reading

FridayOct 22, 2021 9:44 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Global Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Global Small Cap Conference. The event is slated to take place from Oct. 27-28, 2021, with Vivos’ presentation scheduled to begin at 12:15 p.m. ET on Wednesday, Oct. 27. Interested investors should visit https://ibn.fm/jz90E to register for a free spectator pass. A replay will be available for view following…

Continue Reading

ThursdayOct 21, 2021 9:51 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Clinical Hold on Planned Eating Disorder Phase 2a Study

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, reported that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on its upcoming Phase 2a study for eating disorders. According to the announcement, the FDA did not cite a reason for the hold but would provide additional information regarding the hold in the next month. Although the study is now on hold, the company noted that it still expects to move forward with plans to file an IND for its Phase 2a study in fibromyalgia; that…

Continue Reading

WednesdayOct 20, 2021 3:29 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Showcasing Innovations in OSA Treatment at 2021 Annual Breathing Wellness Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has announced the commencement of the 3rd-annual Breathing Wellness Conference presented by The Vivos Institute. The event is taking place at Caesars Palace in Las Vegas, Nevada, from Oct. 20-23, 2021, where dentists and medical doctors from around the world will hear from the industry’s top experts on OSA about its impact on chronic conditions such as heart disease, chronic fatigue and dementia. Attendees will also have the opportunity learn how innovations…

Continue Reading

TuesdayOct 19, 2021 2:21 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid to Bring Airway and Sleep, Oral Health, Orthodontic Therapy Together in Comprehensive Solution

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, have announced a new collaboration. Under the partnership, the companies will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. Additionally, under the agreement, Vivos and Candid will join forces to explore new research and development opportunities for device development and other alliances related to…

Continue Reading

MondayOct 18, 2021 11:57 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS), Candid Collaborate to Deliver Comprehensive Treatment Solution

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, and Candid Care Co., a digital platform for oral healthcare, today announced a new collaboration. The partnership will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network. “By teaming with Candid, we are aiming to provide patients with access not only to our highly effective Vivos System, but also simultaneous access to CandidPro’s novel orthodontic…

Continue Reading